| Landscape of stimulation-responsive chromatin across diverse human immune cells D Calderon, MLT Nguyen, A Mezger, A Kathiria, F Müller, V Nguyen, ... Nature genetics 51 (10), 1494-1505, 2019 | 257 | 2019 |
| CRISPR activation and interference screens decode stimulation responses in primary human T cells R Schmidt, Z Steinhart, M Layeghi, JW Freimer, R Bueno, VQ Nguyen, ... Science 375 (6580), eabj4008, 2022 | 189 | 2022 |
| Pooled knockin targeting for genome engineering of cellular immunotherapies TL Roth, PJ Li, F Blaeschke, JF Nies, R Apathy, C Mowery, R Yu, ... Cell 181 (3), 728-744. e21, 2020 | 183 | 2020 |
| T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic … J Feucht, S Kayser, D Gorodezki, M Hamieh, M Döring, F Blaeschke, ... Oncotarget 7 (47), 76902, 2016 | 177 | 2016 |
| Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice … F Blaeschke, D Stenger, T Kaeuferle, S Willier, R Lotfi, AD Kaiser, ... Cancer Immunology, Immunotherapy 67, 1053-1066, 2018 | 165 | 2018 |
| Strategies of adoptive T-cell transfer to treat refractory viral infections post allogeneic stem cell transplantation T Kaeuferle, R Krauss, F Blaeschke, S Willier, T Feuchtinger Journal of hematology & oncology 12, 1-10, 2019 | 151 | 2019 |
| Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering JR Hamilton, CA Tsuchida, DN Nguyen, BR Shy, ER McGarrigle, ... Cell reports 35 (9), 2021 | 147 | 2021 |
| Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR D Stenger, TA Stief, T Käuferle, S Willier, F Rataj, K Schober, B Vick, ... Blood, 2020 | 140 | 2020 |
| High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails BR Shy, VS Vykunta, A Ha, A Talbot, TL Roth, DN Nguyen, WG Pfeifer, ... Nature biotechnology 41 (4), 521-531, 2023 | 136 | 2023 |
| RASA2 ablation in T cells boosts antigen sensitivity and long-term function J Carnevale, E Shifrut, N Kale, WA Nyberg, F Blaeschke, YY Chen, Z Li, ... Nature 609 (7925), 174-182, 2022 | 122 | 2022 |
| CLEC12A and CD33 co-expression as preferential target on pediatric AML for combinatorial immunotherapy S Willier, P Rothämel, M Hastreiter, J Wilhelm, D Stenger, F Blaeschke, ... Blood, 2020 | 69 | 2020 |
| Rewired signaling network in T cells expressing the chimeric antigen receptor (CAR) R Dong, KA Libby, F Blaeschke, W Fuchs, A Marson, RD Vale, X Su The EMBO Journal 39 (16), e104730, 2020 | 61 | 2020 |
| TCF-1 regulates HIV-specific CD8+ T cell expansion capacity RL Rutishauser, CDT Deguit, J Hiatt, F Blaeschke, TL Roth, L Wang, ... JCI insight 6 (3), 2021 | 54 | 2021 |
| Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation M Döring, KM Cabanillas Stanchi, M Queudeville, J Feucht, F Blaeschke, ... Journal of cancer research and clinical oncology 143, 1281-1292, 2017 | 50 | 2017 |
| Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients F Blaeschke, S Willier, D Stenger, M Lepenies, MA Horstmann, ... Leukemia 34 (10), 2607-2620, 2020 | 39 | 2020 |
| Human HLA-A* 02: 01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo F Blaeschke, U Thiel, A Kirschner, M Thiede, RA Rubio, D Schirmer, ... Oncotarget 7 (28), 43267, 2016 | 32 | 2016 |
| Modular pooled discovery of synthetic knockin sequences to program durable cell therapies F Blaeschke, YY Chen, R Apathy, B Daniel, AY Chen, PA Chen, K Sandor, ... Cell 186 (19), 4216-4234. e33, 2023 | 31 | 2023 |
| Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy F Blaeschke, MC Paul, MU Schuhmann, A Rabsteyn, C Schroeder, ... Cytotherapy 21 (9), 973-986, 2019 | 31 | 2019 |
| CRISPR-Cas9-mediated glucocorticoid resistance in virus-specific T cells for adoptive T cell therapy posttransplantation T Kaeuferle, L Deisenberger, L Jablonowski, TA Stief, F Blaeschke, ... Molecular Therapy 28 (9), 1965-1973, 2020 | 29 | 2020 |
| Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A* 02: 01-specific allorestricted T cell receptor transgenic T cells U Thiel, SJ Schober, I Einspieler, A Kirschner, M Thiede, D Schirmer, ... Oncoimmunology 6 (5), e1312239, 2017 | 28 | 2017 |
